EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC 4.0

Safety and efficacy of extended versus standard interval dosing of anti-CD20 therapy in multiple sclerosis – A meta-analysis

Mahmoud Elkhooly, Rhea Jacob iD, Torge Rempe iD

Multiple Sclerosis Journal – Experimental, Translational and Clinical · 2026-01 · 12 (1)

DOI: 10.1177/20552173261432453 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Multiple Sclerosis Journal – Experimental, Translational and Clinical, online erschienen am 24.03.2026. Verfasst von Mahmoud Elkhooly und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Southern Illinois University School of Medicine, Springfield, IL, USA. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anti-CD20 therapy is a highly effective multiple sclerosis (MS) disease-modifying therapy, but may be complicated by infections, which has led to the utilization of different extended interval dosing (EID) regimens.

Objectives

To compare the efficacy and safety of standard interval dosing (SID) and EID of anti-CD20 therapy in MS.

Methods

We searched PubMed and MS conference abstracts and included all studies comparing distinct cohorts of people with MS (PwMS) treated with SID and EID of anti-CD20 therapy that reported ≥1 efficacy or safety outcome measure. A meta-analysis was performed with effect size calculation (log odds ratio [logOR]) of efficacy and safety outcome measures.

Results

Seventeen studies comparing SID to EID were identified, with 1739 (SID) and 1856 (EID) participants. There was no significant difference in frequencies of PwMS with relapses (logOR = 0.15; p = 0.37), MRI activity (logOR = 0.05; p = 0.7), no evidence of disease activity −3 (logOR = 0.33; p = 0.33), serious infections (logOR = 0.46; p = 0.16), and hypogammaglobulinemia G (logOR = −0.24; p = 0.76).

Conclusions

Data from observational studies suggests that EID of anti-CD20 therapy may have a comparable efficacy and safety profile compared to SID.

Schlagwörter

Stichwörter der Autor:innen

Multiple sclerosisanti-CD20disease-modifying therapyextended interval dosing

Autor:innen und Institutionen

  • Department of Neurology, Southern Illinois University School of Medicine, Springfield, IL, USA.
  • Department of Neurology, College of Medicine, University of Florida, Gainesville, USA.

ORCID-Profile: Rhea Jacob, Torge Rempe

Zitieren

APA

Elkhooly, M., Jacob, R., & Rempe, T. (2026). Safety and efficacy of extended versus standard interval dosing of anti-CD20 therapy in multiple sclerosis – A meta-analysis. Multiple Sclerosis Journal – Experimental, Translational and Clinical, 12(1). https://doi.org/10.1177/20552173261432453

Vancouver

Elkhooly M, Jacob R, Rempe T. Safety and efficacy of extended versus standard interval dosing of anti-CD20 therapy in multiple sclerosis – A meta-analysis. Multiple Sclerosis Journal – Experimental, Translational and Clinical. 2026;12(1). doi:10.1177/20552173261432453

BibTeX
@article{Elkhooly2026,
  author = {Elkhooly, Mahmoud and Jacob, Rhea and Rempe, Torge},
  title = {Safety and efficacy of extended versus standard interval dosing of anti-CD20 therapy in multiple sclerosis – A meta-analysis},
  journal = {Multiple Sclerosis Journal – Experimental, Translational and Clinical},
  year = {2026},
  volume = {12},
  number = {1},
  doi = {10.1177/20552173261432453}
}
Kostenlos starten →